Group 1 - The core viewpoint of the news is that Junshi Biosciences has shown significant trading activity, with a notable increase in stock price and substantial financing and margin trading data indicating a high level of investor interest [1][2] Group 2 - On January 9, Junshi Biosciences' stock price increased by 4.09%, with a trading volume of 520 million yuan [1] - The financing buy-in amount for Junshi Biosciences on the same day was 47.67 million yuan, while the financing repayment was 55.29 million yuan, resulting in a net financing outflow of 7.62 million yuan [1] - As of January 9, the total financing and margin trading balance for Junshi Biosciences was 1.344 billion yuan, with the financing balance accounting for 4.42% of the circulating market value, indicating a high level compared to the past year [1] - In terms of margin trading, on January 9, Junshi Biosciences had a margin repayment of 5,125 shares and a margin sell-out of 3,000 shares, with the sell-out amount calculated at 117,600 yuan [1] - The margin balance was 15.43 million yuan, exceeding the 90th percentile level over the past year, indicating a high level of short selling activity [1] Group 3 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [2] - As of September 30, the number of shareholders for Junshi Biosciences was 35,900, an increase of 15.17% from the previous period, while the average circulating shares per person decreased by 12.96% [2] - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year increase of 35.72% [2] - Among the top ten circulating shareholders, E Fund's Science and Technology Innovation Board 50 ETF held 19.39 million shares, a decrease of 2.82 million shares from the previous period [2] - Another major shareholder, Huaxia's Science and Technology Innovation Board 50 Component ETF, held 18.97 million shares, down by 1.07 million shares from the previous period [2]

Core Viewpoint - Junshi Biosciences (688180.SH) is currently trading at 38.69 yuan, reflecting a decline of 1.30% and is in a state of share price decline since its IPO [1] Fundraising and Financial Performance - Junshi Biosciences was listed on the Shanghai Stock Exchange's STAR Market on July 15, 2020, with an initial issuance of 87.13 million shares at a price of 55.50 yuan per share, raising a total of 4.836 billion yuan, netting 4.497 billion yuan after expenses [2][3] - The company planned to raise 2.7 billion yuan for innovative drug research, industrialization projects, loan repayment, and working capital [2] - The total fundraising from two rounds amounts to 8.612 billion yuan [4] - In the years from 2016 to 2024, the net profit attributable to shareholders has shown consistent losses, with figures of -1.35 billion, -3.17 billion, -7.23 billion, -7.47 billion, -16.69 billion, -7.21 billion, -23.88 billion, -22.83 billion, and -12.81 billion yuan respectively [4] - For the first three quarters of 2025, the company reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, but still recorded a net loss of 0.596 billion yuan, an improvement from the previous year's loss of 0.927 billion yuan [4]

Core Viewpoint - The controlling shareholder and chairman of Junshi Biosciences, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB 100 million over the next 12 months, with a minimum of RMB 50 million allocated for A-shares [2]. Group 1: Shareholding Details - Mr. Xiong Jun currently holds 87,856,618 shares in the company, which includes 87,854,018 A-shares and 2,600 H-shares [3]. - As of the announcement date, Mr. Xiong has cumulatively acquired 100,000 A-shares, representing approximately 0.01% of the total share capital, with a total transaction amount of RMB 3.8384 million [2]. Group 2: Progress of the Shareholding Plan - As of the announcement date, Mr. Xiong and his concerted parties collectively hold 184,083,186 shares, accounting for 17.93% of the total share capital [5]. - The shareholding increase plan is still ongoing, and Mr. Xiong intends to continue purchasing shares during the implementation period [5]. Group 3: Compliance and Regulations - The shareholding increase will comply with relevant regulations from the China Securities Regulatory Commission, Shanghai Stock Exchange, and Hong Kong Stock Exchange regarding changes in equity and sensitive trading periods [7]. - The implementation of this shareholding increase plan will not lead to changes in the company's controlling shareholder or actual controller [7].

Core Viewpoint - Junshi Biosciences (01877) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025 [1] Group 1 - Mr. Xiong intends to purchase both A-shares and H-shares through the Shanghai Stock Exchange and Hong Kong Stock Exchange, with a minimum of RMB 50 million allocated for A-shares [1] - As of the announcement date, Mr. Xiong has already acquired 100,000 A-shares, representing approximately 0.01% of the company's total share capital, with a total transaction value of RMB 3.8384 million [1] - The share purchase plan is still in progress, and Mr. Xiong will continue to buy shares at opportune times during the implementation period of the plan [1]

Core Viewpoint - The chairman and controlling shareholder of Junshi Biosciences (01877), Mr. Xiong Jun, plans to increase his stake in the company by at least RMB 100 million over the next 12 months starting from April 12, 2025 [1] Summary by Relevant Sections - **Shareholding Increase Plan** - Mr. Xiong intends to acquire both A-shares and H-shares of the company, with a minimum of RMB 50 million allocated for A-shares [1] - **Current Shareholding Activity** - As of the announcement date, Mr. Xiong has already purchased 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction value of RMB 3.8384 million [1] - **Future Actions** - The share purchase plan is still in progress, and Mr. Xiong will continue to buy shares opportunistically during the implementation period of the plan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2026年1月9日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、酈仲賢先生、魯琨女士及楊勁 博士。 * 僅供識別之用 证券代码：688180 证券简称：君实生物 公告编号：临 2026-001 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。 茲載列上海君實生物醫藥科技股份有限公司在上海證 ...

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its controlling shareholder and chairman, Mr. Xiong Jun, plans to increase his holdings in the company's A-shares and H-shares by at least RMB 100 million over a 12-month period starting from April 12, 2025 [1] Group 1 - Mr. Xiong intends to invest no less than RMB 50 million in A-shares as part of this plan [1] - As of the announcement date, Mr. Xiong has already acquired 100,000 A-shares through the Shanghai Stock Exchange, representing approximately 0.01% of the company's total share capital, with a total transaction amount of RMB 3.8384 million [1] - The share acquisition plan is still in progress, and Mr. Xiong will continue to purchase shares at opportune times during the implementation period [1]

截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式累计增持公司A股股份10万股， 约占公司总股本的0.01%，累计成交总额为人民币383.84万元。本次增持计划尚未实施完毕，熊俊先生 将继续按照相关增持计划，在增持计划实施期间内择机增持公司股份。 格隆汇1月9日丨君实生物(688180.SH)公布，公司控股股东、实际控制人之一兼董事长熊俊先生拟自 2025年4月12日起12个月内，通过上海证券交易所交易系统与香港联合交易所有限公司允许的方式(包括 但不限于集中竞价和大宗交易等方式)增持公司A股股份及H股股份，合计增持金额不低于人民币1亿 元，其中A股增持金额不低于人民币5000万元。 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码：688180 证券简称：君实生物 公告编号：临 2026-001 上海君实生物医药科技股份有限公司 关于控股股东、实际控制人之一兼董事长 增持股份进展公告 重要内容提示： 上海君实生物医药科技股份有限公司（以下简称"公司"）控股股东、 实际控制人之一兼董事长熊俊先生拟自 2025 年 4 月 12 日起 12 个月内，通过上 海证券交易所交易系统与香港联合交易所有限公司允许的方式（包括但不限于集 中竞价和大宗交易等方式）增持公司 A 股股份及 H 股股份，合计增持金额不低 于人民币 1 亿元，其中 A 股增持金额不低于人民币 5,000 万元。 截至本公告披露日，熊俊先生通过上海证券交易所系统以集中竞价方式 累计增持公司 A 股股份 100,000 股，约占公司总股本的 0.01%，累计成交总额为 人民币 383.84 万元。本次增持计划尚未实施完毕，熊俊先生将继续按照相关增 持计划，在增持计划实施期间内择机增持公司股份。 本次增持计划可能存在因资本市场 ...

Core Viewpoint - Junshi Biosciences is positioned as a leading innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on first-in-class and best-in-class drug development [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, specializing in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7] - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and technical services (0.59%) [7] - As of September 30, 2023, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, and a net profit attributable to shareholders of -596 million yuan, a year-on-year increase of 35.72% [8] Group 2: Product Development and Pipeline - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - Junshi Biosciences is also developing Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with ongoing Phase III trials and several combination studies with Toripalimab [2] - The company is collaborating with various research institutions to develop a monkeypox recombinant protein vaccine, currently in preclinical development [3] Group 3: Market Activity - On January 9, 2024, Junshi Biosciences' stock rose by 4.09%, with a trading volume of 520 million yuan and a market capitalization of 40.246 billion yuan [1] - The stock has seen a net inflow of 42.43 million yuan from major investors, indicating a mixed trend in investor sentiment [4][5] - The average trading cost of the stock is 39.88 yuan, with the current price approaching a resistance level of 39.67 yuan, suggesting potential for upward movement if this level is surpassed [6]